A Prospective Study of EUS Guided Celiac Block

A Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) Effectiveness

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00583271

Enrollment

127

Registered

2007-12-31

Start date

2002-06-30

Completion date

2012-12-31

Last updated

2014-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pancreatitis, Pancreatic Cancer

Brief summary

The purpose of this prospective study is to measure the clinical effectiveness of EUS-guided CB in subjects, 50 who have chronic pancreatitis and 50 who have pancreatic cancer, that are already undergoing celiac block for clinical reasons.

Interventions

DRUGtriamcinolone

80mg of triamcinolone injected into the celiac ganglion during the EUS-CB

DRUG98% dehydrated alcohol

10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with chronic abdominal pain from documented chronic pancreatitis or pancreatic cancer or other visceral malignancy that are undergoing EUS-guided CB (for purposes other than this study) will be eligible to participate in this study. * Patients with chronic pancreatitis and pancreatic cancer must have documented disease by CT, ERCP, or EUS. * No evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol. * Patient must provide signed written informed consent

Exclusion criteria

* Patients that have had a previous celiac plexus block are eligible for this study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026